Home GPCR & G Protein MT Receptor

MT Receptor

Other GPCR & G Protein Related Inhibitors

Hedgehog/Smoothened PKA CGRP Receptor Endothelin Receptor S1P Receptor Cannabinoid Receptor SGLT Opioid Receptor GPR CCR

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S1204 Melatonin Melatonin is a MT receptor agonist, used as a dietary supplement. This compound is a selective ATF-6 inhibitor and downregulates COX-2. It enhances mitophagy and regulates the homeostasis of apoptosis and autophagy.
Antioxidants (Basel), 2025, 14(5)528
Sci Rep, 2025, 15(1):8451
Biochem Biophys Res Commun, 2025, 760:151706
Verified customer review of Melatonin
S1259 Ramelteon Ramelteon (TAK-375) is a novel melatonin receptor agonist for human MT1 and MT2 receptors and chick forebrain melatonin receptors with Ki of 14 pM, 112 pM and 23.1 pM, respectively.
Aging Cell, 2021, e13375
Cell Cycle, 2021, 20(12):1195-1208
Plant Cell Physiol, 2020, 10.1093/pcp/pcaa018
Verified customer review of Ramelteon
S3584 Luzindole Luzindole (N-0774, N-acetyl-2-benzyltryptamine) is a selective melatonin receptor antagonist with Kis of 179 nM for MT1 and 7.3 nM for MT2, respectively.
Commun Biol, 2025, 8(1):396
Aging Cell, 2021, e13375
Int Immunopharmacol, 2021, 96:107787
S4281 Tasimelteon Tasimelteon (BMS 214778, VEC 162) is a selective dual melatonin receptor (MT1/MT2) agonist with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHOeK1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively).
Cells, 2022, 11(21)3467
E6011 Agomelatine hydrochloride Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively. It is also a selective antagonist of 5-HT2C receptors with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively. Blockade of these receptors enhances adrenergic and dopaminergic transmission in the frontocortical regions.

Signaling Pathway Map